Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results

AIDS

Volumn 27, Issue 8, 2013, Pages 1356-1359

  Lacombe, Karine ^a,b,c   Valin, Nadia ^b   Stitou, Hind ^d   Gozlan, Joël ^b   Thibault, Vincent ^d   Boyd, Anders ^c   Poirier, Jean Marie ^b   Meynard, Jean Luc ^b   Valantin, Marc Antoine ^c,d   Bottero, Julie ^a,b,c   Girard, Pierre Marie ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSERM   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EFAVIRENZ; PEGINTERFERON; PEGINTERFERON ALPHA; RALTEGRAVIR; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; MALE; MIXED INFECTION; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ANTIVIRAL AGENTS; COINFECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879102536     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32836138d0     Document Type: Article

References (18)

1. Sulkowski M, Sherman K, Soriano V., Rockstroh J, Dieterich D, Girard P., et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR24 final study results. The 63rd Annual Meeting of the Association for the Study of Liver Diseases; 9-13 November 2012, Boston, MA, USA.
2. Sulkowski M, Pol S, Cooper C., Fainboim H, Slim J, Rivero A., et al. Boceprevir + pegylated interferon + ribavirin for the treatment of HCV/HIV-co-infected patients: end of treatment (week-48) interim results. #47; 5-8 March 2012; Seattle, USA.
3. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012; 61 (SUPPL. 1):i47-i58.
4. EACS. European AIDS Clinical Society, Guidelines - Version 6; October 2011.
5. Thomas DL, Bartlett JG, Peters M.G., Sherman KE, Sulkowski MS, Pham PA Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis 2012; 54:979-983.
6. Colson P, Brouk N, Lembo F., Castellani P, Tamalet C, Gerolami R. Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naive chronically infected patient. Hepatology 2008; 47:766-767.
7. ACTG. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table- for-Grading-Severity-of-Adult-Pediatric-Adverse-Events.pdf. (last accessed: 03/26/2013)
8. Sherman K, Rockstroh J, Dieterich D., Soriano V, Girard P, McCallister S., et al. Telaprevir combination with peginterferon alfa-2a/ribavirin in HCV/HIV coinfected patients: 24-week treatment interim analysis [abstract LB-8]. 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD). San Francisco, USA; 4-8 November 2011.
9. Zeuzem S, Andreone P, Pol S., Lawitz E, Diago M, Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
10. Colombo M, Fernández I, Abdurakhmanov D., Ferreira P, Strasser S, Urbanek P., et al. Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the International Telaprevir Early Access Program. Abstract #LB15. The 63rd Annual Meeting of the Association for the Study of Liver Diseases; 9-13 November, Boston, MA, USA; 2012.
11. Moreno A, Bárcena R, Quereda C., Pérez-Elías M, García-Hoz M, Casado J, et al. Does HIV infection reduce initial safety and efficacy of boceprevir (BOC) or telaprevir (TPV)-based initial therapy in cirrhotic patients in the 'real life'? Abstract S07. The 63rd Annual Meeting of the Association for the Study of Liver Diseases; 9-13 November, Boston, MA, USA; 2012.
12. Rodriguez-Torres M., Gonzalez M, Rossi S. HIV/HCV coin-fected and HCV monoinfected patients have similar early HCV viral kinetics with the potent HCV nucleotide polymerase inhibitor sofosbuvir (SOF). Abstract H1921a. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012); 9-12 September, San Francisco, USA; 2012.
13. De Meyer S., Dierynck I, Ghys A., Beumont M, Daems B, Van Baelen B, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 2012; 56:2106-2115.
14. Kieffer TL, De Meyer S, Bartels DJ, Sullivan J.C., Zhang EZ, Tigges A, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012; 7:e34372.
15. Bartels DJ, Zhou Y, Zhang E.Z., Marcial M., Byrn RA, Pfeiffer T, et al Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008; 198:800-807.
16. Hezode C, Dorival C, Zoulim F., Larrey D, Pol S, Cacoub P., et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non respon-ders. Week 16 analysis of the French Early Access Program (ANRS CO20-CUPIC) in real-life setting. The 63rd Annual Meeting of the Association for the study of Liver Diseases; 9-13 November, Boston, MA, USA; 2012.
17. Picard O, Cacoub P. Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Clin Res Hepatol Gastroenterol 2012; 36:437-440.
18. Cacoub P, Bourliere M, Lubbe J, Dupin N, Buggisch P, Dusheiko G, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56:455-463.